Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Puma Biotechnology, Inc. clinical trials
The registry lists 38 studies whose lead sponsor is Puma Biotechnology, Inc.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 1, 2026.
Keep track of what changes. Save the Puma Biotechnology, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Puma Biotechnology, Inc..
- Puma Biotechnology, Inc.38 studiesSame company
Something wrong?
Focus areas
Conditions Puma Biotechnology, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 38 of 38.
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingNCT06369285Phase 2
- A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)RecruitingNCT07465757Phase 2
- A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerRecruitingNCT06095505Phase 2
- Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsTerminatedNCT01953926Phase 2
- A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibCompletedNCT04366713Phase 2
- An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamideCompletedNCT02400476Phase 2
- A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic SettingCompletedNCT01808573Phase 3
- Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerCompletedNCT00878709Phase 3
- HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of NeratinibTerminatedNCT03786107
- A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid TumorCompletedNCT01128842Phase 1
- Study Evaluating Safety And Tolerability, Solid TumorCompletedNCT00768469Phase 1
- Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast CancerCompletedNCT01111825Phase 1/2
- Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid TumorsCompletedNCT00838539Phase 1
- Study Evaluating HKI-272 in TumorsCompletedNCT00146172Phase 1
- A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid TumorsCompletedNCT00397046Phase 1
- Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast CancerCompletedNCT00741260Phase 1/2
- Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast CancerCompletedNCT00915018Phase 2
- Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast CancerCompletedNCT00300781Phase 2
- Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast CancerCompletedNCT00706030Phase 1/2
- Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast CancerCompletedNCT00777101Phase 2
- A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast CancerCompletedNCT00445458Phase 1/2
- A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast CancerCompletedNCT00398567Phase 1/2
- Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung CancerCompletedNCT01827267Phase 2
- Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid TumorsCompletedNCT00958724Phase 1
- Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung CancerCompletedNCT00266877Phase 2
- Study Evaluating HKI-272 Administered to Healthy SubjectsCompletedNCT00366600Phase 1
- Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy SubjectsCompletedNCT02334501Phase 1
- Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)CompletedNCT00814060Phase 1
- Study Evaluating Oral Administrations of HKI-272 in Healthy Male SubjectsCompletedNCT00550212Phase 1
- Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver DiseaseCompletedNCT00781430Phase 1
- Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of DigoxinCompletedNCT00860223Phase 1
- A Single Dose Bioequivalence Study Of Neratinib In Healthy SubjectsCompletedNCT01142063
- Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of NeratinibWithdrawnNCT00932464Phase 1
- Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)CompletedNCT00708903Phase 1
- Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of NeratinibCompletedNCT00864487Phase 1
- Study Evaluating The Tolerability Of Multiple Doses Of HKI-272CompletedNCT00757809Phase 1
- HKI-272 Ketoconazole Drug Interaction StudyCompletedNCT00380328Phase 1
- Study Comparing 2 New Formulations of HKI-272 in Healthy Adult SubjectsCompletedNCT00498745Phase 1